• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

拉脱维亚家族性高胆固醇血症患者的遗传特征:全基因组测序的首次分析

Genetic Characteristics of Latvian Patients with Familial Hypercholesterolemia: The First Analysis from Genome-Wide Sequencing.

作者信息

Latkovskis Gustavs, Rescenko-Krums Raimonds, Nesterovics Georgijs, Briviba Monta, Saripo Vita, Gilis Dainus, Terauda Elizabete, Meiere Ruta, Skudrina Gunda, Erglis Andrejs, Chora Joana Rita, Bourbon Mafalda, Klovins Janis

机构信息

Institute of Cardiology and Regenerative Medicine, University of Latvia, LV-1004 Riga, Latvia.

Latvian Center of Cardiology, Pauls Stradins Clinical University Hospital, LV-1002 Riga, Latvia.

出版信息

J Clin Med. 2023 Aug 7;12(15):5160. doi: 10.3390/jcm12155160.

DOI:10.3390/jcm12155160
PMID:37568561
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10419451/
Abstract

BACKGROUND

There is limited data on the genetic characteristics of patients with familial hypercholesterolemia (FH) in Latvia. We aim to describe monogenic variants in patients from the Latvian Registry of FH (LRFH).

METHODS

Whole genome sequencing with 30× coverage was performed in unrelated index cases from the LRFH and the Genome Database of Latvian Population. , , , , , , , , , and genes were analyzed. Only variants annotated as pathogenic (P) or likely pathogenic (LP) using the FH Variant Curation Expert Panel guidelines for and adaptations for and were reported.

RESULTS

Among 163 patients, the mean highest documented LDL-cholesterol level was 7.47 ± 1.60 mmol/L, and 79.1% of patients had LDL-cholesterol ≥6.50 mmol/L. A total of 15 P/LP variants were found in 34 patients (diagnostic yield: 20.9%): 14 in the gene and 1 in the gene. Additionally, 24, 54, and 13 VUS were detected in and , respectively. No P/LP variants were identified in the other tested genes.

CONCLUSIONS

Despite the high clinical likelihood of FH, confirmed P/LP variants were detected in only 20.9% of patients in the Latvian cohort when assessed with genome-wide next generation sequencing.

摘要

背景

拉脱维亚关于家族性高胆固醇血症(FH)患者遗传特征的数据有限。我们旨在描述拉脱维亚FH注册登记处(LRFH)患者中的单基因变异。

方法

对来自LRFH和拉脱维亚人群基因组数据库的非亲缘索引病例进行了覆盖度为30×的全基因组测序。对 、 、 、 、 、 、 、 、 和 基因进行了分析。仅报告了根据FH变异整理专家小组指南针对 以及针对 和 的改编版本注释为致病性(P)或可能致病性(LP)的变异。

结果

在163例患者中,记录到的最高LDL-胆固醇水平平均值为7.47±1.60 mmol/L,79.1%的患者LDL-胆固醇≥6.50 mmol/L。在34例患者中总共发现了15个P/LP变异(诊断率:20.9%): 基因中有14个, 基因中有1个。此外,在 、 和 中分别检测到24个、54个和13个意义未明的变异(VUS)。在其他检测的基因中未鉴定出P/LP变异。

结论

尽管FH的临床可能性很高,但在拉脱维亚队列中,通过全基因组下一代测序评估时,仅20.9%的患者检测到确诊的P/LP变异。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a0c/10419451/722a3262c689/jcm-12-05160-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a0c/10419451/722a3262c689/jcm-12-05160-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a0c/10419451/722a3262c689/jcm-12-05160-g001.jpg

相似文献

1
Genetic Characteristics of Latvian Patients with Familial Hypercholesterolemia: The First Analysis from Genome-Wide Sequencing.拉脱维亚家族性高胆固醇血症患者的遗传特征:全基因组测序的首次分析
J Clin Med. 2023 Aug 7;12(15):5160. doi: 10.3390/jcm12155160.
2
ABCG5 and ABCG8 genetic variants in familial hypercholesterolemia.家族性高胆固醇血症中的 ABCG5 和 ABCG8 基因突变。
J Clin Lipidol. 2020 Mar-Apr;14(2):207-217.e7. doi: 10.1016/j.jacl.2020.01.007. Epub 2020 Jan 29.
3
Improvement of Definite Diagnosis of Familial Hypercholesterolemia Using an Expanding Genetic Analysis.通过扩展基因分析改善家族性高胆固醇血症的明确诊断
JACC Asia. 2021 Apr 21;1(1):82-89. doi: 10.1016/j.jacasi.2021.04.001. eCollection 2021 Jun.
4
Unraveling the genetic background of individuals with a clinical familial hypercholesterolemia phenotype.解析具有临床家族性高胆固醇血症表型个体的遗传背景。
J Lipid Res. 2024 Feb;65(2):100490. doi: 10.1016/j.jlr.2023.100490. Epub 2023 Dec 18.
5
Next-generation-sequencing-based identification of familial hypercholesterolemia-related mutations in subjects with increased LDL-C levels in a latvian population.基于下一代测序技术对拉脱维亚人群中低密度脂蛋白胆固醇水平升高的受试者进行家族性高胆固醇血症相关突变的鉴定。
BMC Med Genet. 2015 Sep 28;16:86. doi: 10.1186/s12881-015-0230-x.
6
Next-generation sequencing to confirm clinical familial hypercholesterolemia.下一代测序技术用于确认临床家族性高胆固醇血症。
Eur J Prev Cardiol. 2021 Jul 23;28(8):875-883. doi: 10.1093/eurjpc/zwaa451.
7
Next-generation sequencing to confirm clinical familial hypercholesterolemia.采用新一代测序技术确认临床家族性高胆固醇血症。
Eur J Prev Cardiol. 2020 Jul 27:2047487320942996. doi: 10.1177/2047487320942996.
8
Next generation sequencing to identify novel genetic variants causative of autosomal dominant familial hypercholesterolemia associated with increased risk of coronary heart disease.下一代测序技术用于鉴定导致常染色体显性遗传性高胆固醇血症并伴有冠心病风险增加的新型基因变异。
Gene. 2015 Jul 1;565(1):76-84. doi: 10.1016/j.gene.2015.03.064. Epub 2015 Apr 1.
9
Whole-Gene Duplication of PCSK9 as a Novel Genetic Mechanism for Severe Familial Hypercholesterolemia.PCSK9 全基因复制作为严重家族性高胆固醇血症的一种新的遗传机制。
Can J Cardiol. 2018 Oct;34(10):1316-1324. doi: 10.1016/j.cjca.2018.07.479. Epub 2018 Aug 4.
10
Unusual genetic variants associated with hypercholesterolemia in Argentina.阿根廷高胆固醇血症相关的罕见遗传变异。
Atherosclerosis. 2018 Oct;277:256-261. doi: 10.1016/j.atherosclerosis.2018.06.009.

引用本文的文献

1
Improved Genetic Characterization of Hypercholesterolemia in Latvian Patients with Familial Hypercholesterolemia: A Combined Monogenic and Polygenic Approach Using Whole-Genome Sequencing.拉脱维亚家族性高胆固醇血症患者高胆固醇血症的基因特征改善:一种使用全基因组测序的单基因和多基因联合方法
Int J Mol Sci. 2024 Dec 16;25(24):13466. doi: 10.3390/ijms252413466.

本文引用的文献

1
Screening of and Genes for Sitosterolemia in a Familial Hypercholesterolemia Cascade Screening Program.家族性高胆固醇血症级联筛查项目中甾醇血症和 基因的筛查。
Circ Genom Precis Med. 2022 Jun;15(3):e003390. doi: 10.1161/CIRCGEN.121.003390. Epub 2022 May 12.
2
Twelve Variants Polygenic Score for Low-Density Lipoprotein Cholesterol Distribution in a Large Cohort of Patients With Clinically Diagnosed Familial Hypercholesterolemia With or Without Causative Mutations.在一个有或没有致病突变的临床诊断家族性高胆固醇血症的大队列患者中,十二种变体低密度脂蛋白胆固醇分布多基因评分。
J Am Heart Assoc. 2022 Apr 5;11(7):e023668. doi: 10.1161/JAHA.121.023668. Epub 2022 Mar 24.
3
Familial Hypercholesterolemia: Real-World Data of 1236 Patients Attending a Czech Lipid Clinic. A Retrospective Analysis of Experience in More than 50 years. Part I: Genetics and Biochemical Parameters.
家族性高胆固醇血症:1236名就诊于捷克脂质诊所患者的真实世界数据。50多年经验的回顾性分析。第一部分:遗传学和生化参数。
Front Genet. 2022 Feb 28;13:849008. doi: 10.3389/fgene.2022.849008. eCollection 2022.
4
The Clinical Genome Resource (ClinGen) Familial Hypercholesterolemia Variant Curation Expert Panel consensus guidelines for LDLR variant classification.临床基因组资源(ClinGen)家族性高胆固醇血症变异体管理专家小组共识指南,用于 LDLR 变异体分类。
Genet Med. 2022 Feb;24(2):293-306. doi: 10.1016/j.gim.2021.09.012. Epub 2021 Nov 30.
5
Genetic testing for familial hypercholesterolemia-past, present, and future.家族性高胆固醇血症的基因检测——过去、现在和未来。
J Lipid Res. 2021;62:100139. doi: 10.1016/j.jlr.2021.100139. Epub 2021 Oct 16.
6
2021 ESC Guidelines on cardiovascular disease prevention in clinical practice.2021年欧洲心脏病学会临床实践中心血管疾病预防指南。
Eur Heart J. 2021 Sep 7;42(34):3227-3337. doi: 10.1093/eurheartj/ehab484.
7
Clinical Implications of Monogenic Versus Polygenic Hypercholesterolemia: Long-Term Response to Treatment, Coronary Atherosclerosis Burden, and Cardiovascular Events.单基因与多基因高胆固醇血症的临床意义:长期治疗反应、冠状动脉粥样硬化负担和心血管事件。
J Am Heart Assoc. 2021 May 4;10(9):e018932. doi: 10.1161/JAHA.120.018932. Epub 2021 Apr 23.
8
Twelve years of SAMtools and BCFtools.SAMtools 和 BCFtools 十二年。
Gigascience. 2021 Feb 16;10(2). doi: 10.1093/gigascience/giab008.
9
Sanger Validation of High-Throughput Sequencing in Genetic Diagnosis: Still the Best Practice?桑格法验证高通量测序在基因诊断中的应用:仍是最佳实践吗?
Front Genet. 2020 Dec 2;11:592588. doi: 10.3389/fgene.2020.592588. eCollection 2020.
10
Risk of Premature Atherosclerotic Disease in Patients With Monogenic Versus Polygenic Familial Hypercholesterolemia.单基因家族性高胆固醇血症与多基因家族性高胆固醇血症患者发生早发动脉粥样硬化性疾病的风险。
J Am Coll Cardiol. 2019 Jul 30;74(4):512-522. doi: 10.1016/j.jacc.2019.05.043.